


Acquisition to access global rights to baxdrostat, a novel aldosterone synthase inhibitor in development for blood pressure lowering



Attachments


            Original Link
          

            Original Document
          

            Permalink
          



Disclaimer
AstraZeneca plc published this content on 09 January 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 09 January 2023 07:08:14 UTC.
      

